GlassScriptPhysician profile
Stephen Manocchio
NPI 1891731766
$1,281.24
in general payments reported to CMS, 2019-2025
13 companies · $69.17 in 2025
The $69.17 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $44.10 · 2021: $328 · 2022: $241 · 2023: $104 · 2024: $56.82 · 2025: $69.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $334.32 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Janssen Products, LP | $293.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $168.72 | 2019-2022 | |
| Emd Serono, INC. | $106.38 | 2021-2023 | Serostim |
| Abbvie INC. | $72.69 | 2019-2021 | |
| Braeburn INC. | $61.50 | 2024-2025 | Brixadi |
| Gilead Sciences, INC. | $60.12 | 2021-2023 | |
| Theratechnologies INC. | $54.92 | 2021-2024 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $44.39 | 2019-2022 | |
| Allergan, INC. | $26.18 | 2019 | |
| Indivior INC. | $25.69 | 2019 | |
| Napo Pharmaceuticals INC | $18.27 | 2025 | Mytesi |
| Pfizer INC. | $14.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Manocchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.